SPRO Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of 0.91%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 73.91%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.12%. Given that Spero Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Spero Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..

Spero Therapeutics, Inc. has a beta of 1.448, which suggesting that the stock is 44.796% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Spero Therapeutics, Inc. quarterly revenues are $3M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Spero Therapeutics, Inc.'s net income of -$7.4M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.36x versus 6.99x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of -650.85%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Pyxis Oncology, Inc.'s return on equity of -90.91%.

Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 73.91%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $6.93 which suggests that it could grow by 387.68%. Given that Pyxis Oncology, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Spero Therapeutics, Inc..

Spero Therapeutics, Inc. has a beta of 1.448, which suggesting that the stock is 44.796% more volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.

Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Pyxis Oncology, Inc. quarterly revenues of --. Spero Therapeutics, Inc.'s net income of -$7.4M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.36x versus 30.86x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of --. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Cassava Sciences, Inc.'s return on equity of -86.98%.

Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 73.91%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 275.59%. Given that Cassava Sciences, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Spero Therapeutics, Inc..

Spero Therapeutics, Inc. has a beta of 1.448, which suggesting that the stock is 44.796% more volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -0.628, suggesting its less volatile than the S&P 500 by 162.76%.

Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.

Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. Spero Therapeutics, Inc.'s net income of -$7.4M is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.36x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alpha Teknova, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of -41%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Alpha Teknova, Inc.'s return on equity of -22.95%.

Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 73.91%. On the other hand Alpha Teknova, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 336.89%. Given that Alpha Teknova, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Alpha Teknova, Inc. is more attractive than Spero Therapeutics, Inc..

Spero Therapeutics, Inc. has a beta of 1.448, which suggesting that the stock is 44.796% more volatile than S&P 500. In comparison Alpha Teknova, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Alpha Teknova, Inc. pays out -- of its earnings as a dividend.

Spero Therapeutics, Inc. quarterly revenues are $3M, which are smaller than Alpha Teknova, Inc. quarterly revenues of $10.5M. Spero Therapeutics, Inc.'s net income of -$7.4M is lower than Alpha Teknova, Inc.'s net income of -$4.3M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Alpha Teknova, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.36x versus 2.77x for Alpha Teknova, Inc.. Usually stocks with elevated PS ratios are considered overvalued.